Every September 30th, Rare Cancer Day brings global awareness to the many cancer types that, while individually uncommon, collectively impact millions of lives. At the MRF, this day holds particular meaning as we continue to drive progress for the rarer forms of melanoma—including ocular, mucosal, acral lentiginous and pediatric melanoma—through funding and accelerating medical research, providing educational resources and support and advocating for the community at the federal and state level.

Driving Research for Rare Melanomas 

Rare melanomas pose unique challenges in diagnosis, treatment and outcomes. The MRF remains at the forefront of confronting these challenges by investing directly in scientific innovation. To date, we’ve awarded nearly $4 million in rare melanoma research funding, supporting 46 grants across leading academic institutions throughout the United States. These grants specifically target the biology, treatment and clinical management of the rare melanomas, addressing critical gaps in understanding and care. 

Through this investment, the MRF empowers researchers to explore promising new therapies, investigate genetic and molecular drivers of rare melanoma subtypes and ultimately improve outcomes for patients who have limited standard treatment options. 

Educating and Empowering the Rare Melanoma Community 

Research is only part of the equation. The MRF is also deeply committed to educating and providing resources to rare melanoma patients, caregivers and healthcare professionals and raising public awareness around the rare melanomas. Our robust library of on-demand Ask the Expert webinars and educational materials ensures the rare melanoma community has access to the latest insights on disease management, clinical trials and patient support. 

We encourage everyone to explore these resources through the MRF’s Education Institute, including: 

Spotlight on the MRF's CURE OM Initiative: A Beacon of Hope for Ocular Melanoma Patients 

The CURE OM initiative is the MRF's signature program focused on the most common eye cancer in adults, ocular melanoma, diagnosed in approximately 2,000 Americans each year. Since its inception, CURE OM has united patients, researchers and clinicians to elevate awareness, fund innovative research and advocate for systemic change. 

Through CURE OM, we continue to advance ocular melanoma science while fostering a supportive and informed patient community. 

Learn more about CURE OM here. 

Advocating for Federal Funding for Rare Melanoma Research 

Our impact doesn’t stop at the lab or the lecture hall. The MRF is a strong voice on Capitol Hill, advocating for federal research funding through programs like the Melanoma Research Program (MRP) within the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP). 

Thanks to the efforts of MRF advocates, the MRP has become a vital lifeline for rare melanoma research, enabling critical studies that may not otherwise receive funding. This Rare Cancer Day, we renew our call for policymakers to prioritize rare cancer research and continue supporting programs that fuel lifesaving discoveries. 

To get involved in our advocacy efforts, visit the MRF Advocacy Center. 

Every Voice Matters 

Rare Cancer Day is a reminder that every voice, every discovery and every act of advocacy matters. The MRF stands with every patient, family member, clinician and researcher committed to ending melanoma—rare or common. Together, we are shaping a future where rare does not mean forgotten. To make a tax-deductible donation to specifically support a loved one battling a rarer form of melanoma click below.

We’re thrilled to welcome the melanoma community to the 24th Annual New York Gala on Thursday, October 30 at Cipriani Broadway — an unforgettable evening dedicated to celebrating progress, honoring champions and fueling the fight against melanoma. Guests will enjoy an elegant cocktail reception, a gourmet dinner, a “Chance to Win,” an exciting live auction, and a powerful awards program recognizing extraordinary contributions across the melanoma community. 

This year, we are proud to honor Tate Edwards Kirk, MD, with the CURE OM Vision of Hope Award for his exemplary patient care, groundbreaking research and scientific leadership. Delcath Systems, Inc. will receive the Corporate Leadership Award for their longstanding commitment to sun safety and skin health. Shereene Idriss, MD, will be presented with the Influencer Award for her innovative use of social media to raise melanoma awareness. Kathy Madden, MSN, FNP-BC, AOCNP, APHN, will be recognized with the Compassionate Care Award for her unwavering dedication and exceptional care for patients. And finally, Dr. Allie Dashow, Jimmy Hexter and Amy Lipin will be honored with the Courage Award for their remarkable strength and resilience in their melanoma journeys.  

As we prepare for this special evening, we’re also honored to highlight the stories of our incredible donors, whose commitment makes events like this possible. Longtime supporter, Tom Chiusano, shared:

Stories like this remind us why the New York Gala is more than just an event—it’s a celebration of resilience, impact and the power of community to change lives. 

Don’t forget – Superyacht Captain, TV Personality, Melanoma Patient and Advocate, Jason Chambers, will headline as our event emcee for the evening! Limited tickets are still available, don’t miss out on purchasing your ticket today! For further information about the New York Gala, to purchase tickets, learn about sponsorship opportunities or to make a tax-deductible donation, click the button below.

Join us on October 16, for an educational webinar on mucosal melanoma, one of the rarest and most challenging forms of melanoma. This session will explore current treatment options and highlight emerging research aimed at improving patient outcomes. 

We will be joined by Kasey Couts, PhD, Assistant Professor and Co-Director of the CU Center for Rare Melanomas, who will share expert insights from clinical trials. We will also hear an important patient perspective from Toni English, a stage IV mucosal melanoma survivor and patient advocate. 

Join us on October 30, for an insightful webinar exploring the emerging role of minimal residual disease (MRD) testing in melanoma management. This session will provide an overview of MRD testing and its types, share recent data and highlight how experts are integrating MRD testing into melanoma treatment and care. 

We will be joined by Dr. Beitsch, a surgical oncologist trained at MD Anderson Cancer Center and the John Wayne Cancer Institute. Don’t miss this opportunity to learn how MRD testing is shaping the future of melanoma management and improving patient outcomes.

In recognition of Hispanic Heritage Month, the MRF reaffirms its commitment to ensuring that melanoma education and resources are accessible to everyone. We are proud to offer Spanish-language materials to better support patients and caregivers in Hispanic communities, including: 

These resources are free to download or order and share within your community to help raise awareness and support those impacted by melanoma. You can place your order using the order form here.